Want to join the conversation?
$WRI reaffirmed its 2016 recurring FFO per share guidance of $2.27-2.31. However, $WRI lowered its reported FFO per share outlook to range of $2.21-2.26 from previous forecast of $2.26-2.31 due to the non-recurring deferred tax expense recognized in 1Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?